论文部分内容阅读
目的:了解沙利度胺联合托烷司琼治疗乳腺癌辅助化疗所致恶心呕吐的疗效及不良反应。方法:将52例术后化疗的乳腺癌患者随机分为A、B两组,每组各26例,A组:静脉用托烷司琼5mg,第1天+口服地塞米松5mg,1天2次,第1天;B组:静脉用托烷司琼5mg,第1天+口服沙利度胺25mg,1天2次,第1天。评价两组的止吐效果和副作用。结果:46例患者可评价疗效,两组恶心呕吐控制情况完全控制、基本控制、轻度控制、未控制百分率分别为:8.0%vs.33.3%、52.0%vs.57.1%、32.0%vs.9.5%、8.0%vs.0%,治疗有效率为60.0%vs.90.5%(χ2=5.498,P=0.019),差异有统计学意义。两组患者腹泻、困倦、凝血功能异常、骨髓抑制和感觉异常等副作用的发生率差异无统计学意义。结论:联合应用沙利度胺能够有效控制乳腺癌辅助化疗相关性恶心呕吐,副作用容易耐受,是可供选择使用的止吐药物。
Objective: To investigate the efficacy and adverse reactions of thalidomide combined with tropisetron in the treatment of nausea and vomiting induced by adjuvant chemotherapy for breast cancer. Methods: 52 cases of postoperative breast cancer patients were randomly divided into A and B groups, 26 cases in each group, A group: intravenous tropisetron 5mg, the first day + oral dexamethasone 5mg, 1 day 2 times, day 1; group B: tropisetron intravenous 5 mg, day 1 + oral thalidomide 25 mg, 1 day 2 times, first day. The antiemetic effect and side effects were evaluated in both groups. RESULTS: Forty-six patients could be evaluated for efficacy. The complete control, basic control, mild control, and uncontrolled percentage of nausea and vomiting control in the two groups were: 8.0% vs. 33.3%, 52.0% vs. 57.1%, 32.0% vs. 9.5 %, 8.0% vs.0%, the effective rate of treatment was 60.0% vs. 90.5% (χ2=5.498, P=0.019), and the difference was statistically significant. There was no significant difference in the incidence of side effects such as diarrhea, drowsiness, abnormal coagulation, bone marrow suppression, and paresthesia in both groups. Conclusion: The combined use of thalidomide can effectively control the chemotherapy-related nausea and vomiting associated with breast cancer, and the side effects are easily tolerated. It is an antiemetic drug that can be used as an option.